Skip to content

Menten AI

Menten AI is pioneering generative AI to design cyclic peptide therapeutics for drug targets beyond the reach of small molecules and biologics.

Last updated September 2, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Menten AI is a company that develops a physics-based generative AI platform called MAUD 1.0 for peptide macrocycle drug design. The platform is validated across the preclinical discovery pipeline and is trusted by top-10 pharma partners. Menten AI is backed by leading VCs.

History

Menten AI is an American biotech quantum computing company. It is pioneering generative AI to design cyclic peptide therapeutics. Its proprietary platform, MAUD 1.0, integrates generative AI, physics-based modeling, and quantum chemistry simulations to design novel peptide macrocycles from scratch. The platform has been validated across the preclinical pipeline, demonstrating nM-level potency, membrane permeability, favorable DMPK properties, and in vivo efficacy. Menten AI partners with top-10 pharma leaders such as Bristol Myers Squibb and is backed by investors including Social Impact Capital, Uncork Capital, Khosla Ventures, and Y Combinator.

Products and positioning

  • MAUD 1.0

Sources3 sources

Cite this profile: Cite the canonical profile. /brand-wiki/menten-ai · Editorial policy · How profiles are compiled